Skip to content
PubMed This is a summary of 12 peer-reviewed journal articles Updated
Neuromuscular medicine

Long-Term Monitoring and Your Surveillance Plan

At a Glance

People with GMPPB-related LGMD R19 may need an individualized long-term surveillance plan, including heart rhythm and ultrasound, breathing tests while sitting and lying down, sleep-related breathing checks, bone density evaluation, and physical therapy.

Because GMPPB-related disease can change over time and varies significantly between people, long-term care involves regular “check-ups” for your heart, lungs, and bones [1][2]. Even if your symptoms seem stable, this proactive monitoring helps your care team catch and manage potential issues before they become serious [3].

Cardiac Monitoring

Although many people with the LGMD R19 phenotype do not have heart problems, some cases have shown specific changes like long QT interval (a rare change in the heart’s electrical rhythm) or left-ventricular dilation (an enlargement of the heart’s main pumping chamber) [4].

  • Standard Screening: Experts generally recommend a baseline ECG (to check rhythm) and echocardiogram (an ultrasound of the heart) at the time of diagnosis [5].
  • Follow-up: While a strict universal schedule for GMPPB is not yet established, many specialists follow a routine of repeating these tests on an individualized schedule based on age, phenotype, and symptoms [5]. If you experience palpitations, fainting, or chest pain, you should be evaluated by a cardiologist sooner.

Respiratory Health

In the adult-onset (LGMD) form, the muscles used for breathing are often “spared,” meaning they stay stronger for longer [1]. However, in more severe or congenital forms, monitoring is vital [6].

  • Pulmonary Function Tests (PFTs): These tests measure how much air your lungs can hold and how forcefully you can breathe out. One critical measurement is the Forced Vital Capacity (FVC) [7].
  • The Sitting-to-Supine Test: Your doctor should measure your FVC while you are sitting up and again while you are lying flat (supine). If your lung function drops by more than 20% when you lie down, it is an important screening clue that your diaphragm (the main breathing muscle) may be weakening [6].
  • Sleep Monitoring: If you have signs of nocturnal hypoventilation (not breathing deeply enough while asleep), such as morning headaches, daytime sleepiness, or frequent night waking, your doctor may order a proper sleep study or overnight monitoring that includes carbon dioxide (CO2) measurement, because checking oxygen alone can miss inadequate ventilation [7][8]. If symptoms like worsening breathlessness, inability to lie flat, confusion, or severe morning headaches occur, seek prompt medical review rather than waiting for routine monitoring.

Bone and Orthopedic Health

Maintaining a strong “frame” is essential for staying mobile. Muscle weakness can sometimes lead to changes in the skeleton or a loss of bone density [9].

  • Scoliosis and Contractures: Your physical therapist or orthopedist will regularly check for scoliosis (a curve in the spine) and contractures (stiffness in the joints like the ankles, knees, or hips) [9]. Catching these early allows for better management with bracing or therapy.
  • Bone Density (DXA Scan): Because reduced mobility can lead to thinner bones (osteoporosis), a DXA scan may be used to measure bone mineral density [10].
  • Nutrition: Your team may monitor your levels of Vitamin D and Calcium [11]. Keeping these levels healthy is a simple but important way to protect your bones from fractures if you happen to fall.

Summary Surveillance Table

System Test When to Evaluate
Heart ECG & Echocardiogram Baseline assessment; repeat individualized by age/symptoms [5]
Lungs PFTs (Sitting & Supine) Baseline; repeat based on age, phenotype, and prior findings [6]
Sleep Sleep Study with CO2 When screening tests drop or symptoms (headaches, fatigue) appear [7]
Bones DXA Scan Baseline if reduced mobility; repeat based on fracture risk [10]
Muscles Physical Therapy Ongoing, individualized assessment to guide safe mobility [1]

Note: This schedule should be individualized based on your specific symptoms and your doctor’s assessment. [12] Routine CK testing at fixed intervals is generally not recommended as it does not reliably measure progression or current weakness, and it may add burden without changing care [1].

Common questions in this guide

How often should someone with LGMD R19 have heart tests?
An ECG and echocardiogram are generally recommended when LGMD R19 is diagnosed. Follow-up timing is individualized according to age, symptoms, disease pattern, and previous findings. Palpitations, fainting, or chest pain should prompt earlier medical evaluation.
What do sitting and lying-down breathing tests show?
Forced vital capacity, or FVC, measures how much air a person can move in and out of the lungs. Comparing FVC while sitting and lying flat can help identify diaphragm weakness; a drop of more than 20% when lying down is an important warning sign for further assessment.
When might a person with LGMD R19 need a sleep study?
A sleep study or overnight monitoring may be recommended for morning headaches, daytime sleepiness, frequent nighttime waking, or other signs of shallow breathing during sleep. Monitoring carbon dioxide can detect inadequate ventilation that an oxygen measurement alone may miss.
Does LGMD R19 monitoring include a bone density scan?
A DXA scan may be considered when mobility has decreased or fracture risk is a concern because reduced movement can weaken bones. The care team may also monitor vitamin D and calcium levels and check for scoliosis or joint contractures.
What can help monitor scoliosis and contractures in LGMD R19?
A physical therapist or orthopedist can regularly assess the spine and joints for curvature or stiffness. Finding these changes early may allow bracing, therapy, and mobility planning to help preserve function.
Should routine CK blood tests be done to track LGMD R19?
Routine CK testing at fixed intervals is generally not recommended for tracking progression in this condition. CK levels may not reliably show current weakness or changes over time, and repeated testing may not alter care.

Get notified when new evidence is published on GMPPB-related limb-girdle muscular dystrophy R19.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

References

References (12)
  1. 1

    GDP-Mannose Pyrophosphorylase B (GMPPB)-Related Disorders.

    Chompoopong P, Milone M

    Genes 2023; (14(2)) doi:10.3390/genes14020372.

    PMID: 36833299
  2. 2

    Familial dystroglycanopathy: same mutation, different phenotypes.

    Khadilkar SV, Khade SS, Mahajan Bhanushali JP

    Practical neurology 2026; doi:10.1136/pn-2026-005222.

    PMID: 42248683
  3. 3

    Limb-Girdle Muscular Dystrophies.

    Liewluck T

    Continuum (Minneapolis, Minn.) 2025; (31(5)):1344-1371 doi:10.1212/cont.0000000000001615.

    PMID: 41037170
  4. 4

    Mutations in GMPPB Presenting with Pseudometabolic Myopathy.

    Panicucci C, Fiorillo C, Moro F, et al.

    JIMD reports 2018; (38()):23-31 doi:10.1007/8904_2017_25.

    PMID: 28456886
  5. 5

    2022 HRS expert consensus statement on evaluation and management of arrhythmic risk in neuromuscular disorders.

    Groh WJ, Bhakta D, Tomaselli GF, et al.

    Heart rhythm 2022; (19(10)):e61-e120 doi:10.1016/j.hrthm.2022.04.022.

    PMID: 35500790
  6. 6

    Comparison of sitting and supine forced vital capacity in collagen VI-related dystrophy and laminin α2-related dystrophy.

    Meilleur KG, Linton MM, Fontana J, et al.

    Pediatric pulmonology 2017; (52(4)):524-532 doi:10.1002/ppul.23622.

    PMID: 28085238
  7. 7

    Evaluation and management of dyspnea as the dominant presenting feature in neuromuscular disorders.

    Mamarabadi M, Mauney S, Li Y, Aboussouan LS

    Muscle & nerve 2024; (70(5)):916-928 doi:10.1002/mus.28243.

    PMID: 39267292
  8. 8

    Sleep in pediatric neuromuscular disorders.

    Pascoe JE, Zygmunt A, Ehsan Z, Gurbani N

    Seminars in pediatric neurology 2023; (48()):101092 doi:10.1016/j.spen.2023.101092.

    PMID: 38065635
  9. 9

    Orthopedic and Surgical Management of the Patient With Duchenne Muscular Dystrophy.

    Apkon SD, Alman B, Birnkrant DJ, et al.

    Pediatrics 2018; (142(Suppl 2)):S82-S89 doi:10.1542/peds.2018-0333J.

    PMID: 30275252
  10. 10

    Bone quality in LAMA2-related muscular dystrophy and SELENON-related congenital myopathy, a one-year prospective natural history study.

    Bouman K, Dittrich ATM, Groothuis JT, et al.

    Neuromuscular disorders : NMD 2024; (34()):105-113 doi:10.1016/j.nmd.2023.11.008.

    PMID: 38160563
  11. 11

    Bones and muscular dystrophies: what do we know?

    Wood CL, Straub V

    Current opinion in neurology 2018; (31(5)):583-591 doi:10.1097/WCO.0000000000000603.

    PMID: 30080716
  12. 12

    The burden of bone disease in Duchenne muscular dystrophy: age-specific prevalence of osteoporosis and low bone density.

    Nasomyont N, Tian C, Hornung L, et al.

    Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA 2026; (37(5)):1319-1328 doi:10.1007/s00198-026-07963-1.

    PMID: 41912872

This information about surveillance for GMPPB-related LGMD R19 is for education and does not replace medical advice. Your neuromuscular team should determine the timing of heart, breathing, sleep, bone, and mobility assessments for your specific situation.